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Abstract
Background: Few adolescents and young adults (AYAs, 15-39  years old) enroll 
onto cancer clinical trials, which hinders research otherwise having the potential to 
improve outcomes in this unique population. Prior studies have reported that AYAs 
are more likely to receive cancer care in community settings. The National Cancer 
Institute (NCI) has led efforts to increase trial enrollment through its network of NCI-
designated cancer centers (NCICC) combined with community outreach through its 
Community Clinical Oncology Program (CCOP; replaced by the NCI Community 
Oncology Research Program in 2014).
Methods: Using AYA proportional enrollment (the proportion of total enrollments who 
were AYAs) as the primary outcome, we examined enrollment of AYAs onto SWOG 
therapeutic trials at NCICC, CCOP, and non-NCICC/non-CCOP sites from 2004 to 
2013 by type of site, study period (2004-08 vs 2009-13), and patient demographics.
Results: Overall, AYA proportional enrollment was 10.1%. AYA proportional en-
rollment decreased between 2004-2008 and 2009-2013 (13.1% vs 8.5%, P < .001), 
and was higher at NCICCs than at CCOPs and non-NCICC/non-CCOPs (14.1% vs 
8.3% and 9.2%, respectively; P < .001). AYA proportional enrollment declined sig-
nificantly at all three site types. Proportional enrollment of AYAs who were Black or 
Hispanic was significantly higher at NCICCs compared with CCOPs or non-NCICC/
non-CCOPs (11.5% vs 8.8, P = .048 and 11.5% vs 8.6%, P = .03, respectively).
Conclusion: Not only did community sites enroll a lower proportion of AYAs onto 
cancer clinical trials, but AYA enrollment decreased in all study settings. Initiatives 
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1 |  INTRODUCTION
Significant outcome disparities continue to plague adoles-
cents and young adults (AYAs, 15-39 years old) with cancer, 
particularly certain patient subsets defined by cancer type, 
presence of metastatic disease, and sociodemographic factors 
that include racial/ethnic minority and low socioeconomic 
status.1 Numerous studies have documented that enrollment 
of AYAs onto cancer clinical trials is significantly lower 
than that of younger patients and is similar to the low en-
rollment reported in older adults.2-6 Poor representation of 
AYAs on clinical trials limits improvements in survival for 
this population, including determination of optimal treatment 
approaches and age-related differences in cancer and host 
biology.2-4,7-12
The US National Cancer Institute (NCI) has developed 
research networks focused on improving survival and health 
outcomes for cancer patients through the conduct of large-
scale clinical trials, including the National Clinical Trials 
Network (NCTN), the NCI Cancer Centers Program, and the 
NCI Community Oncology Research Program (NCORP). 
The NCTN provides funding and clinical trial infrastructure 
support to over 3000 sites via membership in NCTN net-
work groups, including the SWOG Cancer Research Network 
(SWOG; formerly the Southwest Oncology Group). The NCI 
Cancer Centers Program consists of 70 NCI-designated Cancer 
Centers (NCICC) that are members of the NCTN, including 
49 Comprehensive Cancer Centers and 14 Clinical Cancer 
Centers. The Community Clinical Oncology Program (CCOP), 
predecessor to the NCORP, was launched in 1983 to increase 
access to NCI-sponsored clinical trials by funding communi-
ty-based cancer treatment centers. It has accounted for one-
third of all NCI trial enrollments.13-18 In 2014, the CCOP was 
transitioned to the NCORP, which retains the historical CCOP 
focus on clinical trial access in community settings.
Prior studies indicate that AYAs predominantly receive 
cancer care at community rather than urban academic sites, 
suggesting that community-based sites with access to clin-
ical trials should be well positioned to recruit this popu-
lation.19-22 However, a recent study of AYA enrollment 
onto Children's Oncology Group (COG) trials showed that, 
in fact, a significantly lower proportion of AYAs was en-
rolled at CCOP compared with non-CCOP sites; further, 
proportional AYA enrollment at CCOP sites decreased 
significantly from 2004-08 to 2009-2013.8 To gain a more 
complete understanding of AYA enrollment patterns in both 
the pediatric and adult cooperative group settings, the ob-
jective of this current study was to evaluate AYA enrollment 
onto SWOG trials during the same time interval at NCI-
designated Cancer Centers, CCOP sites, and other sites that 
participate in NCI-funded clinical trials. We hypothesized 
that the highest AYA proportional enrollment would be ob-
served at CCOP sites and that, due to heightened awareness 
of AYA cancer disparities, AYA proportional enrollment 
would have increased at all sites over time.
2 |  METHODS
2.1 | Data sources, definitions, and trial 
inclusion criteria
Enrollment data for all NCTN cooperative groups are regularly 
reported to the NCI. Utilizing the SWOG and NCI Division of 
Cancer Prevention (DCP) databases, we examined AYA pro-
portional enrollment onto SWOG therapeutic trials, including 
Phase II and Phase III cancer treatment trials (n = 63) for selected 
cancers that were open during some portion of the period 2004-
2013. As previously described,8 AYA proportional enrollment 
was defined as the number of AYA patients (15-39 years old) 
enrolled divided by the total number of all patients enrolled. 
Cancer treatment trials were defined as studies evaluating the 
impact of specific treatment regimens/approaches on survival 
outcomes. Trials for patients with both newly diagnosed and 
relapsed/refractory disease were included. Supportive care tri-
als and nonintervention studies were excluded. Trials for cancer 
types that are rare among AYAs, eg, multiple myeloma and 
prostate cancer, were also excluded. Trials that met these inclu-
sion criteria, along with those that were excluded, are listed in 
Supplemental Table S1.
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2.2 | Statistical analysis
We compared AYA proportional enrollment among (a) 
NCICC sites, (b) CCOP sites, and (c) non-NCICC/non-
CCOP sites (ie, sites that were neither NCICC nor CCOP 
sites).8 Additionally, we evaluated temporal trends in en-
rollment patterns by era (2004-2008 vs 2009-2013), 
AYA age subsets (<30 vs ≥30  years) and race/ethnicity. 
Differences were assessed using Fisher's exact test and the 
χ2 test of proportions.
3 |  RESULTS
3.1 | Overall AYA clinical trial enrollment
During the overall period 2004-2013, there were 23  328 
total enrollments onto SWOG trials, of which 2380 were 
AYAs (proportional AYA enrollment = 10.2%). Total en-
rollments at NCICC sites, CCOP sites, and non-NCICC/
CCOP sites were 5604, 8856, and 13  868, respectively. 
Between 2004-2008 and 2009-2013, the number of open 
therapeutic trials increased from 34 to 47. Although the ab-
solute number of AYAs enrolled increased slightly from 
1130 to 1250 (by 120; +10.6%), the number of older pa-
tients increased to a much greater extent, from 7492 to 
13 456 (by 5964; +55.7%). The proportion of AYAs en-
rolled thus declined markedly from 13.1% (1130/8622) to 
8.5% (1250/14706; P  <  .001). Because AYA enrollment 
may be influenced by which trials are open at any given 
time, we determined proportional AYA enrollment only for 
those trials open during both study periods (n = 18) (Table 
S1) and found it also declined significantly from 13.7% to 
10.5% (P < .001).
3.2 | AYA clinical trial enrollment by type of 
treatment site
For the entire period 2004-2013, NCICC sites demonstrated 
significantly higher proportional enrollment of AYAs 
compared with CCOP sites and non-NCICC/CCOP sites 
(14.1% vs 8.3% and 9.2%, respectively; P <  .001 for both 
comparisons), while the difference in proportional AYA 
enrollment between CCOP and non-NCICC/non-CCOP 
sites was not significant (P = .09; Figure 1A). Between the 
periods 2004-2008 and 2009-2013, AYA proportional en-
rollment decreased significantly at all three categories of 
sites (P <  .001; Figure 1B). CCOPs experienced the larg-
est decrease in proportional enrollment of AYAs followed 
by non-NCICC/CCOPs and NCICCs (−42.1%, −35.7%, and 
−31.9%, respectively).
3.3 | AYA clinical trial enrollment by age
In order to characterize the impact of age within the 
broad range of AYAs, we compared proportional enroll-
ment for patients 15-29 vs 30-39  years old. The group 
with 15-29  year-olds had a significantly lower propor-
tion of enrollment than those aged 30-39 at NCICC sites 
(4.9% [n = 273] vs 9.2% [n = 515], P <  .001); at CCOP 
sites (1.8% [n  =  69] vs 6.5% [n  =  250], P  <  .001); and 
at non-NCICC/non-CCOP sites (1.9% [n = 266] vs 7.3% 
F I G U R E  1  Proportion of therapeutic study enrollments that were adolescents and young adult (AYA) by treatment site type and time 
interval. AYA proportional enrollment was significantly greater at NCICC compared with CCOP and non-NCICC/CCOPs during the years 2004-
2013 (Panel A). AYA proportional enrollment decreased significantly between the years 2004-08 and 2009-13 at NCICC, CCOP, and non-NCICC/
CCOP sites (Panel B). On both panels, n represents the number of enrollments
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[n  =  1007], P  <  .001). Enrollment for both these AYA 
subgroups significantly decreased over time at NCICCs 
and non-NCICC/non-CCOPs, and proportional enrollment 
for patients age 30-39 significantly decreased at CCOPs 
(Figure 2).
3.4 | AYA clinical trial enrollment by 
race and ethnicity
Because few studies have assessed minority AYA enroll-
ment onto cancer clinical trials, we also evaluated AYA 
enrollment by race and ethnicity. At NCICC, CCOP, and 
non-NCICC/non-CCOP sites the proportions of AYA en-
rollments that were Black was 11.5% (n  =  91), 10.3% 
(n = 33), and 8.8% (n = 112), respectively; the proportions 
that were Hispanic were 11.5% (n  =  91), 9.1% (n  =  29), 
and 8.6% (n  =  109); the proportions that were Asian/
Pacific Islander were 6.2% (n = 49), 2.2% (n = 7), and 6.7% 
(n  =  85); and the proportions that were Native American 
were 0.6% (n = 5), 1.3% (n = 4), and 0.7% (n = 7), respec-
tively. AYA enrollment for the two largest AYA minority 
groups, Black and Hispanic patients, is shown in Figure 3. 
Both the proportional enrollment of AYAs who were Black 
and of those who were Hispanic were significantly higher at 
NCICCs compared with non-NCICC/non-CCOPs (P = .05 
and P = .03, respectively; Figure 3A,B). Also, the propor-
tional enrollment of AYAs who were Asian/Pacific Islander 
was significantly higher at NCICCs compared to CCOPs 
(P  =  .009). The proportion of Hispanic AYAs increased 
significantly over time only at non-NCICC/non-CCOP sites 
(8.6% vs 11.7%, P < .001; Figure 3B). There was no statisti-
cally significant change in Black, Asian/Pacific Islander, or 
Native American AYA enrollment in any site type (Figure 
3A). However, the numbers of AYA patients in these groups 
were particularly small.
4 |  DISCUSSION
While the overall NCI clinical trial enterprise has been highly 
successful,13,17 our studies of AYA enrollment in two coopera-
tive oncology groups document that, among all categories of 
institutions offering NCI-funded trials, AYA representation as 
a proportion of total enrollments is lowest, and decreased the 
most over time, at community-based sites. This finding is both 
unexpected and worrisome, given that AYAs predominantly 
receive their cancer care in the community setting.8,19,20,22 This 
study of SWOG AYA enrollment, combined with our previous 
study of COG AYA enrollment8 demonstrates that recruitment 
of AYAs onto NCI-sponsored clinical trials is a considerable 
challenge for CCOP and non-NCICC/non-CCOP sites. Despite 
numerous publications documenting low levels of AYA partic-
ipation in cancer clinical trials,4,6,7,11 as well as those highlight-
ing AYA cancer outcomes disparities that might be ameliorated 
through the conduct of cancer clinical trials,4,7,8 our two studies 
reveal that proportional representation of AYAs on NCI-funded 
clinical trials actually fell significantly between 2004 and 2013. 
This study makes clear that simply providing community sites 
with access to NCI-sponsored clinical trials is not enough to 
recruit a substantial proportion of AYAs. Our results add ur-
gency to the well-documented need to increase AYA enroll-
ment, which, despite heightened awareness, is getting worse as 
reflected by this measure. Our findings suggest that offering 
NCI-funded trials in the community setting must be accompa-
nied by targeted recruitment strategies aimed at the AYA popu-
lation in order to be as successful at AYA participation as large 
academic sites.
Maximizing AYA enrollment onto clinical trials is im-
portant because AYAs constitute a relatively small number 
of participants on either pediatric or adult studies. For ex-
ample, on AAML0531, a COG study for patients with acute 
myeloid leukemia (AML) age 1 month-29.99 years, of 1070 
participants only 163 (15%) were over 15 years of age, and 
F I G U R E  2  Proportion of therapeutic study enrollments that were adolescents and young adult (AYA) by age group, treatment site type, and 
time interval. The figure shows that the proportional enrollment for patients 15-29 y old was low at all sites. Between 2004-2008 and 2009-2013, 
for patients 30-39 y old proportional enrollment decreased significantly at all sites. For patients 15-29 y old, proportional enrollment decreased 
significantly at NCICCs and non-NCICC/non-CCOPs, but not CCOPs. The value for n represents the number of enrollments
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only 13 (1%) were 21 years or older.23 Conversely, on S0106, 
a SWOG trial for patients with AML age 18-60 years, of 595 
participants only 57 (19%) were less than age 35  years.24 
With AYAs being outnumbered in this fashion, it is ex-
tremely difficult to determine AYA-specific outcomes or 
to design studies with AYA-specific aims. Even if NCTN 
groups were to combine efforts and develop AYA-specific 
trials, for some cancer types the number of participants may 
still be marginal for achieving adequate power to detect out-
come differences in treatment comparisons. Currently, S1826 
is an NCTN trial for treatment of advanced-stage Hodgkin 
lymphoma jointly developed by SWOG and COG for patients 
age 12 years and older, thus encompassing the entire AYA 
age range (NCT03907488). For appropriate cancers, such 
collaborative efforts probably represent the best mechanism 
for studying AYA-specific outcomes. Although it is generally 
acknowledged that the chief value of cancer clinical trials is 
to improve outcomes over time for patient populations, one 
study found that AYAs were nearly three times more likely 
to receive appropriate initial therapy if they were enrolled on 
a clinical trial than if not enrolled.25 Thus, for AYAs an ad-
ditional incentive for clinical trial participation may be opti-
mizing treatment for individual patients.
Our prior study that demonstrated low and falling AYA 
proportional enrollment onto COG trials during 2008-2014 
raised the question whether AYA enrollment onto adult co-
operative group trials may have increased concurrently and 
accounted for that drop.8 This study, conducted for the same 
time period, clearly shows that AYA proportional enrollment 
onto adult cooperative group trials also decreased over time. 
Due to the AYA age range encompassing both older pediatric 
and younger adult patients, effective strategies for increasing 
AYA enrollment require close collaboration and cooperation 
between COG and the adult focused NCTN groups, as well 
as between pediatric and medical oncology providers at the 
site level.
Our results demonstrate that AYAs in their twenties 
represent a very small proportion of patients on adult-fo-
cused cancer clinical trials. The very low enrollment pro-
portion of younger AYAs (2.6%) compared with older 
AYAs (7.6%) in our study likely reflects, at least in part, 
the lower incidence of cancer among AYAs. To better un-
derstand patterns of AYA enrollment by type of institution, 
we would need to know the total number of incident cancer 
cases diagnosed at the treatment centers included in this 
study. Unfortunately, reporting these denominator data to 
NCI is not currently required. In one study of AYA clinical 
trial enrollment, cancer registry data were used to identify 
incident cases of AYA cancer  that were then individually 
linked to clinical trial enrollment records [10], but such 
linkage ability is not uniformly available. This inability to 
determine accurately the “AYA denominator” of new can-
cer cases diagnosed at treatment sites for any given report-
ing period remains a major roadblock to acquiring a fully 
informed understanding of AYA clinical trial enrollment 
patterns. Further, the absolute number of younger AYAs is 
very small (only 608 in this age group were enrolled onto 
these trials during this period), making it difficult to con-
duct studies for young AYAs with specific cancer types. 
Such trials are necessary for defining optimal cancer treat-
ment including the role of new agents, effective supportive 
care approaches, and elucidating the underlying prognostic 
significance of differences in cancer and host biology that 
can lead to improved AYA outcomes. The success of such 
F I G U R E  3  Proportion of adolescents and young adult (AYA) therapeutic study enrollments that were Black or Hispanic by treatment site 
type and time interval. The proportion of AYA enrollments who were Black was significantly higher at NCICCs compared with non-NCICC/
CCOPs (Panel A). The proportion of AYA enrollments who were Hispanic was significantly higher at NCICCs compared with non-NCICC/non-
CCOPs (Panel B). The proportion of AYA enrollments who were Hispanic increased significantly only at non-NCICC/non-CCOP sites between 
2004-08 and 2009-2013. On both panels, n represents the number of enrollments
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trials will necessarily involve collaboration between the 
adult NCTN groups and the COG.
Our study suggests that AYA racial and ethnic minori-
ties were underrepresented on the clinical trials examined 
here. We found that 9.9% of AYAs enrolled were Black and 
9.6% were Hispanic. While our study methodology precludes 
knowing how these precentages relate to the actual numbers 
of minority AYAs diagnosed with cancer, the proportions 
we observed are well below US population percentages for 
these groups, which are in the range of approximately 17% 
and 14%, respectively.26 Few studies have examined the re-
lationship between race/ethnicity and cancer trial enrollment 
for AYA patients. In a case-linked analysis of AYA clinical 
trial enrollment in the context of an NCI-designated compre-
hensive cancer center, Latinos were found to be more likely 
to enroll than non-Hispanic whites, while Blacks were less 
likely.3 Understanding the impact of sociodemographic vari-
ables on AYA clinical trial enrollment is increasingly relevant 
with minorities projected to increase from 36% of the total 
US population in 2010 to approximately 50% in 2040. As in 
the case of age, our study calls attention to the importance of 
being able to determine accurately the “AYA denominator” in 
all categories of race, ethnicity and SES groups. Our compar-
isons of minority enrollment showed small or nonsignificant 
changes over time, likely due to limited numbers of AYA pa-
tients in these groups.
Strengths of our study include the large number of enroll-
ments analyzed (n = 23 328), the use of well-established and 
robust data sources (the SWOG and NCI DCP databases), 
the assessment of enrollment patterns over a recent decade 
that aligns with our previous study of AYA enrollments onto 
COG trials, and the gaining of new insights into Black and 
Hispanic AYA enrollment. Limitations include the method-
ology of utilizing AYA proportional enrollment (proportion 
of study enrollments that are AYA) in lieu of the proportion 
of enrolled AYAs among all AYAs diagnosed with cancer 
at each site. As discussed earlier, the inability to obtain the 
“AYA denominator,” that is, the total number of AYAs di-
agnosed with cancer at each site, precludes that type of as-
sessment. While overall study enrollments increased by 71% 
(6084 enrollments) between the two study periods (largely 
resulting from the increase in the total number of open trials), 
AYA enrollments accounted for only 2% (120 enrollments) 
of this increase. In this regard, it is important to emphasize 
that trials not relevant to AYAs (eg, prostate) were excluded 
from our study.
In 2014 the CCOP transitioned into the NCORP to expand 
the reach and impact of the program and align its goals with 
the NCI National Clinical Trials Network.27,28 Given the lim-
ited and decreasing AYA proportional enrollment on NCTN 
cooperative group trials at these community sites, a study 
led by the COG AYA Oncology Discipline Committee is in 
progress to identify the most prevalent and targetable AYA 
enrollment barriers at NCORP sites. Having documented that 
AYA representation on SWOG Cancer Research Network 
clinical trials decreased over the past decade, it is hoped that 
these results will stimulate additional research to develop and 
implement interventions aimed at increasing AYA enroll-
ment, most notably at community sites, onto NCI-sponsored 
cancer clinical trials.
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